Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2026)

Foghorn Therapeutics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $52.3 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 1.22% year-over-year to $52.3 million; the TTM figure through Mar 2026 stood at $52.3 million (up 1.22% YoY), while the FY2025 annual figure was $43.2 million, down 5.29% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $52.3 million, up from $43.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $337.8 million in Q3 2023, with the low at $30.1 million in Q1 2022.
• The 5-year median for Current Deferred Revenue is $33.9 million (2023), against an average of $57.7 million.
• Peak annual rise in Current Deferred Revenue reached 2494.76% in 2022, while the deepest fall reached 90.28% in 2022.
• Foghorn Therapeutics' Current Deferred Revenue stood at $32.8 million in 2022, then advanced by 5.27% to $34.6 million in 2023, then soared by 32.0% to $45.6 million in 2024, then decreased by 5.29% to $43.2 million in 2025, then climbed by 21.09% to $52.3 million in 2026.
• Business Quant data shows FHTX's Current Deferred Revenue at $52.3 million in Q1 2026, $43.2 million in Q4 2025, and $65.3 million in Q3 2025.